Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: J Pharmacokinet Pharmacodyn. 2015 May 31;42(4):375–389. doi: 10.1007/s10928-015-9419-z

Table 3.

Fit of E=Emax(1-Xn/(X50n+Xn)) to PK/PD model predicted (Figure 2) and experimentally observed [12] mouse rifampin dose-fractionation data (E = log10 CFU, Emax = maximum E, X is a PK/PD index, X50 is the value of X at E = Emax/2, and n is a shape parameter.)

X Emax X50 n R2 CV%
Pred. Obs. Pred. Obs. Pred. Obs. Pred. Obs. Pred. Obs.
AUC24/MIC 5.9 5.9 4.3 ×103 3.9 ×103 0.65 0.70 0.95 0.95 5.4 6.0
Cmax/MIC 5.9 6.2 5.0 ×102 2.8 ×102 0.63 0.57 0.78 0.81 11 9.1
T>MIC 5.8 5.7 1.1 ×102 1.1 ×102 4.8 11 0.66 0.46 14 18

R2: coefficient of determination.

CV%: percent coefficient of variation (of root mean square error).

Pred.: calculated from PK/PD model predicted log10 CFU v.s. X shown in Figure 2

Obs.: calculated from experimentally observed log10 CFU v.s. X reported in Jayaram et al. [12]